Most patients with ovarian cancer require systemic therapy upfront and again on recurrence. Treatment advances over the past decade have been few, but bevacizumab prolongs disease remission, if not survival. Other targeted agents have not been effective, but emerging data for experimental agents suggest this outlook may change. In her presentation at the NCCN 18th Annual Conference, Dr. Deborah K. Armstrong reviewed findings supporting intraperitoneal chemotherapy, the use of bevacizumab, the use of neoadjuvant chemotherapy, and the potential of poly (ADP-ribose) polymerase (PARP) inhibitors and other newer agents.
|Original language||English (US)|
|Number of pages||4|
|Journal||JNCCN Journal of the National Comprehensive Cancer Network|
|Issue number||5 SUPPL.|
|State||Published - May 1 2013|
ASJC Scopus subject areas